Novel oral anticoagulants: New challenges for anesthesiologists in bleeding patients

Anesthesiology

Volumn 116, Issue 1, 2012, Pages 9-11

  Spahn, Donat R ^a   Korte, Wolfgang ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN;

ACUTE CORONARY SYNDROME; ANESTHESIST; BLEEDING TENDENCY; DEEP VEIN THROMBOSIS; EDITORIAL; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KNEE ARTHROPLASTY; LUNG EMBOLISM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; STROKE; THROMBOELASTOGRAPHY; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; FACTOR VIIA; MALE; MORPHOLINES; PROTHROMBIN; RECOMBINANT PROTEINS; THIOPHENES;

EID: 84655163134     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318238c070     Document Type: Editorial

References (16)

1. Levy JH, Key NS, Azran MS: Novel oral anticoagulants: Implications in the perioperative setting. ANESTHESIOLOGY 2010; 113:726-45
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-51
3. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-75 (Pubitemid 351930851)
4. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators: Extended duration rivaroxaban versus shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet 2008; 372:31-9
5. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-86 (Pubitemid 351930852)
6. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 Investigators: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial. Lancet 2009; 373:1673-80
7. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama C-M: Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. ANESTHESIOLOGY 2012; 116:94-102
8. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA: Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: A study in 9 Swiss laboratories. Thromb Res 2011, Aug 11. [Epub ahead of print]
9. Mani H, Hesse C, Stratmann G, Lindhoff-Last E: Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106:156-64
10. Samama MM, Guinet C, Le Flem L, Gerotziafas G In vitro response of dabigatran and rivaroxabanon on thrombin generation (CAT) and fibrin formation (ROTEM). Paper presented at: 23rd Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 26, 2011; abstract P-TU-229
11. Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E: Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood 2008; 112:3825
12. Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542-7 (Pubitemid 27519853)
13. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U: High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia- like conditions in a cell-based model system. Br J Haematol 2001; 114:114-20 (Pubitemid 32702643)
14. Perzborn E, Tinel H Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. Paper presented at: 22nd Congress of the International Society on Thrombosis and Haemostasis, Boston, Massachusetts, July 13, 2009; abstract PP-MO-183
15. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, Locker GJ, Laczika K, Knapp S, Watzke H: Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 1999; 25:1105-10 (Pubitemid 29525066)
16. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124:1573-9